**REGISTERED COMPANY NUMBER: 07227937 (England and Wales) REGISTERED CHARITY NUMBER: 1136413**
## **REPORT OF THE TRUSTEES AND UNAUDITED FINANCIAL STATEMENTS**
**FOR THE YEAR ENDED 30 APRIL 2023**
## **FOR**
## **HEARTBURN CANCER UK**
Hopper Williams & Bell Limited Chartered Accountants Highland House Mayflower Close Chandler's Ford Eastleigh Hampshire SO53 4AR
**HEARTBURN CANCER UK**
**CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2023**
||**Page**|
|---|---|
|**Reference and Administrative Details**|1|
|**Report of the Trustees**|2 to 8|
|**Statement of Trustees' Responsibilities**|9|
|**Independent Examiner's Report**|10|
|**Statement of Financial Activities**|11|
|**Balance Sheet**|12 to 13|
|**Notes to the Financial Statements**|14 to 24|
**HEARTBURN CANCER UK**
**REFERENCE AND ADMINISTRATIVE DETAILS FOR THE YEAR ENDED 30 APRIL 2023**
|**TRUSTEES**|Professor R C Fitzgerald|
|---|---|
||Ms B A Huntingdon|
||W Mathers (appointed 4.7.22)|
||Mrs M E McCord|
||O J Stovin|
||T Thornton-Jones|
||T J Underwood|
||Mrs J Carr (resigned 17.5.22)|
||P Carr (resigned 17.5.22)|
||M J C Farrier (appointed 1.11.23)|
||Ms J Stevenson Timini (appointed 1.12.23)|
|**REGISTERED OFFICE**|Grove House|
||Lutyens Close|
||Chineham Court|
||Basingstoke|
||Hampshire|
||RG24 8AG|
|**REGISTERED COMPANY**|07227937 (England and Wales)|
|**NUMBER**||
|**REGISTERED CHARITY**|1136413|
|**NUMBER**||
|**INDEPENDENT EXAMINER**|Hopper Williams & Bell Limited|
||Chartered Accountants|
||Highland House|
||Mayflower Close|
||Chandler's Ford|
||Eastleigh|
||Hampshire|
||SO53 4AR|
Page 1
## **Heartburn Cancer UK End of Year Report – FY22-23**
## **Heartburn Cancer UK’s Mission:**
To be a respected UK source of awareness and information on the risks of ignoring persistent heartburn, encouraging the public to seek medical advice, to champion research to enable an earlier diagnosis to save lives, and to support those living with reflux, Barrett’s oesophagus, and oesophageal cancer.
## **Achievements and Performance**
We have returned to a more normal year post pandemic with positive results in our fundraising income and charity activities. We have positively impacted the lives of 300 individuals living with oesophageal cancer, Barrett’s oesophagus and who are experiencing persistent heartburn. We have provided support, information and signposting via email, phone, our growing online community and face to face peer support groups. We have seen demand for our work and the impact we are able to have improve wellbeing, physical and mental health and the day-to-day quality of life of our beneficiaries.
## **Patient Support**
- Support groups in East Anglia and Basingstoke returned to normal by either meeting in person or finding a hybrid solution. London chose to continue with Zoom meetings. Basingstoke has now returned to meetings and is thriving again following the pandemic.
- Our online patient support group on Facebook has continued to grow and now has 100 new members with over 250 in total. Helpful and supportive conversations between various patient groups continue to provide excellent peer support with some very uplifting exchanges.
- Our clinical trustees Professor Rebecca Fitzgerald and Professor Tim Underwood, Sarah Davies (Dietician) and Dr Oliver Stovin (retired GP) as Dietician in Residence and Doctor in Residence respectively provide invaluable support, content, and help the team answer questions on a variety of topics with their clinical expertise.
- The team supports patients via phone calls, emails, the website and questions through social media.
- We had discussions regarding establishing a support group at Chase Farm Hospital with the encouragement of the clinical nurse specialist. We had our first meeting in February.
Page 2
## **Research and Diagnosis**
- We have invested significant time and effort in working with the Project DELTA team at Cambridge, to continue and complete the study with our Mobile Diagnostic Unit (MDU). It was important to provide assistance as required by the DELTA team. Many useful lessons about using the Cytosponge™ in primary care have been learnt and we have developed a good working relationship with our partners. The data and learning from this project will help feed our plans for suitable collaborations to enable further use of the unit post DELTA, help the Cytosponge™ progress to being adopted into regular care pathways and support the ordering of our second mobile diagnostic unit.
- HCUK were also invited to be a non-funded partner on Cytoprime 1 and then Cytoprime 2. These are both SBRI funded projects and support further initiatives that offer the Cytosponge™ in primary care. HCUK have been particularly involved in PPIE (Patient and Public Involvement and Engagement).
- Professor Tim Underwood continues in his role as Surgical Specialist Lead for improvements to Oesophageal Cancer (OC) treatment and care. This financial support will continue in partnership with AUGIS when a new clinician is recruited to the role.
- Our chairman has spent much time and resource representing the charity and patients on numerous research projects as a lay representative and project advisor, exemplified in writing letters of support, providing patient advocacy, and reviewing and editing documents to ensure their suitability for a lay audience.
- We provided patients who were involved in giving feedback for the PEUGIC (Post Endoscopy Upper GI Cancer) study which explores missed cancers post endoscopy.
- HCUK’s involvement with supporting NICE (National Institute for Health and Care Excellence) activity continued and we formed a new relationship supporting the SMC (Scottish Medical Consortium).
## **General Awareness**
- Our raising of awareness has been maintained using our social media platforms, Facebook, Twitter, LinkedIn, Instagram and we have recently added Tik Tok. Followers have increased across all platforms.
- Our website continues as the mainstay of our awareness campaigning and provision of information for patients and the public. This is signposted from social media and new materials are regularly updated. We have continued to take advantage of the Google Ads grant available to us as a charity ($10,000 each month).
- To expand our helpful video library this year we created some video snippets suitable for social media that would support understanding of the Cytosponge™ and the opportunity to self-refer if you met specific criteria. This was in collaboration with Face TV and initially for our work with DELTA and the MDU. We also featured on a video with Cancer52 that shared our work.
- The charity enjoyed some regular articles in The Basingstoke Gazette, double page articles in the Charity pages of Expert Witness magazine and an online and printed healthcare review for a wide range of healthcare professionals in NI, Scotland and Wales via Kyron Media. We also had an article in the PCA Professional Cricketers Association Magazine featuring Tim Underwood.
- We featured on the radio with Rebecca Fitzgerald and Oliver Stovin in some relevant locations for the mobile unit and DELTA and to promote our Golf Day at Worplesdon.
- Tim Underwood, his Clinical Nurse Specialist, an oesophagectomy patient and Fiona Labrooy our Operations Manager presented at a meeting for Pharmaceutical representatives in London, with some first-class feedback from our audience.
Page 3
- HCUK continued its 2-year sponsorship agreement with six golf courses spread across the UK. This sees our messages shared in their clubs and amongst a prime audience of middleaged men for the duration of the agreement.
## **Fundraising**
- Individual fundraising events where supporters collect funds through Just Giving was a great income stream with nearly £67k raised. Website donations gathered nearly £19k and corporate donations raised in excess of £22k. Trusts and Foundations raised £20k and “In memoriam giving”, including funds raised from Much Loved and donations specifically noted as being given in memory raised over £27k. While our organised event income including activities like Golf days was over £19k.
- We have had a very positive and supportive relationship with corporate partners the Lanesborough. Our Chairman Mimi McCord and Fiona Labrooy our Operation’s Manager, presented to the Senior Management Team to share the charities activities, and in turn they showed us the touch points for guests at the hotel that introduce the charity. The Lanesborough also supported us with wonderful auction prizes and teams for events.
- We had a successful relationship with Worplesdon Golf Club who made us their charity of the year following the death of former captain John Harridge from OAC. This included various fundraising activities including a Grand Golf Day.
- A new corporate partnership was established with DOC Cleaning whose team had also been impacted by oesophageal cancer.
- Grant applications have been very successful with £20k raised across the year with a focus on our support and core costs.
## **Income Analysis**
Page 4
Grants Awarded FY22-23
D'oyley Carie-.
Core Costs
É3k
Awards for
All.. Support
£IOk
Chart Area
Albert
core Costs
£5k
H05Pltal Saturday
Fufit*= Support £2k
Plans for the Future"
Our Obl•ctlv•s
Highlight & inforrn the importan
diseaseearly,
Ensure wide unde
derto th15ewth the dtsvase, fami
memberswd kl•wested members of public
Develop & promote llxal supwrt netwoths forsufferers
Maintain and Ènha
btK)k8roup supporting
sufferers
8 medical bdTr
at this can affe
anyo
K & dlfferentlatefromoth
cancer charits
Promotethealmsof
AWARENESS
EDUCATION
RESEARCH
Use research finding5toeducate the publ
Devekip partnershlps ¥th 0therorganlsatns & like-
rninded group5
Promote Coll4ratIon amongst mernber5 of the
medital profession. & IDbbygovl. pharma industry &
mllar Chare$ lor improved pubficty aknJt t
dangersef persistent heartburn
Use HCUX'S inflvence to effect changes around how
the dase is perceryed. deterted. diagnosed &
treèted.
suPrt researth & tnalsde*ned to red/preVeI)I
heartbjm, Barretvs OesoFthagus & Oesophageal
Cancer
Conbnue to supportthe Suwcal SpÈt141rty Lead ro
undertaken byTim vndèrwt4
Page 5
## **Our 20[th] Anniversary**
2023 is the 20th anniversary of the charity and we intend to exploit this milestone through adventure challenges, major charity events and use of media opportunities. We want to highlight the focus of the charity to raise awareness of the possible dangers of ignoring persistent heartburn and its link to Barrett’s oesophagus and oesophageal adenocarcinoma. We will do this through our ‘Demanding Hope’ campaign as well as via our awareness messages using PR, social media, our website and any other appropriate channel and opportunities. This will enable an earlier diagnosis of cancer when curative treatment is still possible. In the 20 years of the charity’s existence the prognosis for this cancer remains appalling. A particular highlight will be in February for Oesophageal Cancer Awareness Month when we intend to join forces with Cyted and The Lanesborough, London, to raise awareness using the mobile unit and provide some capsule sponge testing through clinical partnerships.
## **Early Diagnosis & Awareness using the Mobile Diagnostic Unit**
During 2022, HCUK’s awareness and early diagnosis activity was focused on the continuation of the Mobile Diagnostic Unit (MDU) in partnership with the DELTA project. The unit enabled primary care activity using the Cytosponge™ in Essex and then Suffolk, following on from its time in Cambridge in 2021. This allowed up to 1500 tests to be undertaken by invited patients who fulfilled the criteria using the GP database, and self-referral patients over 40 years of age suffering from heartburn and self-medicating with antacids. Results will contribute to the DELTA Project’s efforts to have the Cytosponge™ adopted as a mainstream early diagnostic test by the NHS. In 2023 the unit will complete its work with DELTA and will continue work supporting the progress of the Cytosponge™ at the start of Cancer Research’s BEST4 study which will help demonstrate the Cytosponge™ diagnostic test can save lives. The unit will also be used as part of SBRI funded Cytoprime2’s study continuing to develop the pathways for use of the Cytosponge™ in primary care for surveillance of Barrett’s, case finding and triage. This also sees HCUK fulfilling a supportive role in PPIE (Patient and Public involvement and Engagement) as a non-funded partner. There has been further interest to use the unit from Integrated Care Boards (ICBs) and Cancer Alliances who want the opportunity to use the capsule sponge test in their areas, which will instigate us having our second unit built.
## **Social Media**
Social media and our website has continued to form a major element of HCUK’s awareness work. The HCUK website has continued to be developed to widen exposure using the various optimisation tools available, and with newly- developed SEO ‘capabilities’ this will extend reach to a wider audience. Social media channels have been exploited to their maximum potential with available resources. The launch and growth of the Facebook-based Barrett’s and Oesophageal Cancer Online Support Group suggests this was a welcome addition to HCUK’s support offering for those living with these conditions and their families (252 members at time of writing). We plan to further develop our support and information provision in 2023 by growing our face-to-face support groups, extending our online support group activities to include a series of speakers and Q & A sessions. We will be adding to our video library and will refresh our website information and literature to ensure it remains accessible and up to date. HCUK are also going to form the HCUK Patient Advocacy Forum to support and review information, literature and activities involving patients.
Page 6
## **Financial Review**
Total reserves are £217,337 (2022: £158,244), of this £129,256 (2022: £74,023) is restricted and within restricted funds are held the fixed asset balance for the Mobile Diagnostic Unit. See note 18 for the detailed descriptions and balances on these funds.
## **Reserves Policy**
It is the policy of the charity that unrestricted funds, which have not been designated for a specific use should be maintained at a level equivalent to six months' expenditure, which is calculated to be in the region of £58,000. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities whilst consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.
## **Risks**
The Trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to the major risks.
Page 7
## **Structure, Governance and Management**
The following served as trustees during the year: Mrs M E McCord Prof R C Fitzgerald Mr M Thornton-Jones Prof T J Underwood Mrs B A Huntingdon Dr O J Stovin Mr W Mathers Mrs J Carr (resigned 17.5.22) P Carr (resigned 17.5.22)
The above are also Directors for the purposes of company law.
The Board have the statutory power to appoint new trustees under the terms of the Trust Deed and provide the necessary training in order that they may fulfil their obligations as Trustees.
None of the Trustees has any beneficial interest in the company. The Directors are members of the company and guarantee to contribute £1 in the event of a winding up.
The charity is governed by the Board of Trustees which is responsible for formulating the strategies and policies of the charity including exercising financial controls.
22 Dec 2023 Approved by order of the board of trustees on ............................................. and signed on its behalf by:
........................................................................
Mrs M E McCord - Trustee
Page 8
**HEARTBURN CANCER UK**
**STATEMENT OF TRUSTEES' RESPONSIBILITIES FOR THE YEAR ENDED 30 APRIL 2023**
The trustees (who are also the directors of Heartburn Cancer UK for the purposes of company law) are responsible for preparingthe Report of the Trustees and the financialstatements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.
The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Page 9
**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF HEARTBURN CANCER UK**
## **Independent examiner's report to the trustees of Heartburn Cancer UK ('the Company')**
I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 April 2023.
## **Responsibilities and basis of report**
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination,I report in respect of my examinationof your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.
## **Independent examiner's statement**
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accountingand reportingby charities (applicable to charitiespreparingtheir accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examinationto which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
N R Whitemore FCCA The Association of Chartered Certified Accountants
Hopper Williams & Bell Limited Chartered Accountants Highland House Mayflower Close Chandler's Ford Eastleigh Hampshire SO53 4AR
22 Dec 2023 Date: .............................................
Page 10
**HEARTBURN CANCER UK**
## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 APRIL 2023**
|Unrestricted
fund
Notes
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
2
**71,609**
**Charitable activities**
5
Other charitable activities
**18,810**
Other trading activities
3
**225**
Investment income
4
**944**
**Total**
**91,588**
**EXPENDITURE ON**
Raising funds
6
**17,757**
**Charitable activities**
7
Early diagnosis
**-**
Awareness
**22,301**
Research and education
**7,245**
Support
**18,113**
Charity running costs
**22,308**
Other charitable activities
**-**
**Total**
**87,724**
**NET INCOME**
**3,864**
**RECONCILIATION OF FUNDS**
Total funds brought forward
**84,221**
**TOTAL FUNDS CARRIED FORWARD**
**88,085**|Restricted
funds
£
**82,295**
**1,030**
**-**
**-**
**83,325**
**-**
**28,096**
**-**
**-**
**-**
**-**
**-**
**28,096**
**55,229**
**74,023**
**129,252**|**2023**
**Total**
**funds**
**£**
**153,904**
**19,840**
**225**
**944**
**174,913**
**17,757**
**28,096**
**22,301**
**7,245**
**18,113**
**22,308**
**-**
**115,820**
**59,093**
**158,244**
**217,337**|2022
Total
funds
£
130,092
37,143
651
12|
|---|---|---|---|
||||167,898|
||||48,535
24,934
32,753
7,329
9,026
13,515
-|
||||136,092|
||||31,806
126,438|
||||158,244|
The notes form part of these financial statements
Page 11
**HEARTBURN CANCER UK**
## **BALANCE SHEET 30 APRIL 2023**
|Unrestricted
fund
Notes
£
**FIXED ASSETS**
Tangible assets
15
**-**
**CURRENT ASSETS**
Debtors
16
**2,452**
Cash at bank
**88,129**
**90,581**
**CREDITORS**
Amounts falling due within one year
17
**(2,500)**
**NET CURRENT ASSETS**
**88,081**
**TOTAL ASSETS LESS CURRENT**
**LIABILITIES**
**88,081**
**NET ASSETS**
**88,081**
**FUNDS**
18
Unrestricted funds
Restricted funds
**TOTAL FUNDS**|Restricted
funds
£
**16,234**
**9,716**
**103,306**
**113,022**
**-**
**113,022**
**129,256**
**129,256**|**2023**
**Total**
**funds**
**£**
**16,234**
**12,168**
**191,435**
**203,603**
**(2,500)**
**201,103**
**217,337**
**217,337**
**88,081**
**129,256**
**217,337**|2022
Total
funds
£
21,646
36,666
117,777
154,443
(17,845)
136,598
158,244
158,244
84,221
74,023
158,244|
|---|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2023.
The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2023 in accordance with Section 476 of the Companies Act 2006.
The trustees acknowledge their responsibilities for
- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
The notes form part of these financial statements
continued...
Page 12
**HEARTBURN CANCER UK**
**BALANCE SHEET - continued 30 APRIL 2023**
These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.
The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by: 22 Dec 2023
............................................. M E McCord - Trustee
The notes form part of these financial statements
Page 13
**HEARTBURN CANCER UK NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2023**
## **1. ACCOUNTING POLICIES**
## **Basis of preparing the financial statements**
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
## **Financial reporting standard 102 - reduced disclosure exemptions**
The charitable company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':
- the requirements of Section 7 Statement of Cash Flows.
## **Income**
Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.
Donations by way of grants are recognised either on receipt or Invoice, whichever is earlier. Donations and associated gift aid from on-line sites such as Just Giving and Virgin Giving are recognised as and when paid by those sites, after they have been verified and processed, and includes donations remitted to the charity from those sites within the financial year. These donations are recorded net of processing charges.
Other donations and legacies are recognised on receipt. Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of the donation.
Donated services and facilities are included in the Statement of Financial Activities in the year they are received at the value of the gift to the charity, provided the value of the gift can be measured reliably.
The expense element of such donations is reflected in resources expended in the appropriate expense category.
## **Expenditure**
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.
Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.
## **Tangible fixed assets**
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - Straight line over 5 years
Tangible fixed assets are stated at cost less depreciation. Cost represents purchase price together with any incidental costs of acquisition.
continued...
Page 14
**HEARTBURN CANCER UK NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
## **1. ACCOUNTING POLICIES - continued**
## **Taxation**
The charity is exempt from corporation tax on its charitable activities.
## **Fund accounting**
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.
## **Pension costs and other post-retirement benefits**
The charitable company operates a defined contribution pension scheme. Contributionspayable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.
## **Going concern**
At the time of preparing the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
## **Financial instruments**
The charitable company only has financial assets and liabilities of a kind that qualify as basic financial instruments.Basic financial instrumentsare initiallyrecognised at transaction value and subsequently measure at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.
## **2. DONATIONS AND LEGACIES**
|Donations and gifts
Donations in kind
Grants
Grants received, included in the above, are as follows:
Other grants|**2023**
**£**
**124,904**
**9,000**
**20,000**
**153,904**
**2023**
**£**
**20,000**|2022
£
116,698
13,394
-|
|---|---|---|
|||130,092|
|||2022
£
-|
Page 15
continued...
**HEARTBURN CANCER UK**
**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
|**3.**
**OTHER TRADING ACTIVITIES**
Sale of merchandise
**4.**
**INVESTMENT INCOME**
Deposit account interest
**5.**
**INCOME FROM CHARITABLE ACTIVITIES**
Activity
Golf day income
Other charitable activities
Other
Other charitable activities
**6.**
**RAISING FUNDS**
**Raising donations and legacies**
Staff costs
Website and social media
General fundraising costs
Travel and training costs
Office expenses
Printing, post and advertising
Golf day event costs
Computer expenses|**2023**
**£**
**225**
**2023**
**£**
**944**
**2023**
**£**
**19,640**
**200**
**19,840**
**2023**
**£**
**3,215**
**608**
**8,231**
**134**
**485**
**600**
**4,326**
**158**
**17,757**|2022
£
651
2022
£
12
2022
£
37,143
-|
|---|---|---|
|||37,143|
|||2022
£
15,242
1,032
4,566
100
2,655
1,305
22,987
648|
|||48,535|
Page 16
continued...
**HEARTBURN CANCER UK**
**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
## **7. CHARITABLE ACTIVITIES COSTS**
|Direct
Support
Costs (see
costs (see
note 8)
note 10)
£
£
Early diagnosis
**28,096**
**-**
Awareness
**22,301**
**-**
Research and education
**7,245**
**-**
Support
**18,113**
**-**
Charity running costs
**19,164**
**3,144**
**94,919**
**3,144**
**8.**
**DIRECT COSTS OF CHARITABLE ACTIVITIES**
**2023**
**£**
Staff costs
**61,087**
Office expenses
**9,179**
Computer expenses
**3,003**
Printing, post and advertising
**1,785**
Website and social media
**11,545**
Sundries
**141**
Insurance
**1,221**
Consumables
**819**
Travel and training costs
**574**
Depreciation
**5,412**
Interest payable and similar charges
**153**
**94,919**
**9.**
**GRANTS PAYABLE**
**2023**
**£**
Research and education
**-**|Totals
£
**28,096**
**22,301**
**7,245**
**18,113**
**22,308**|
|---|---|
||**98,063**|
||2022
£
43,933
7,655
3,069
7,574
9,285
229
190
5,203
-
5,412
754|
||83,304|
||2022
£
3,125|
continued...
Page 17
**HEARTBURN CANCER UK**
**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
## **10. SUPPORT COSTS**
|**SUPPORT COSTS**|||
|---|---|---|
|||Governance|
|||costs|
|||£|
|Charity running costs||**3,144**|
|**NET INCOME/(EXPENDITURE)**|||
|Net income/(expenditure) is stated after charging/(crediting):|||
||**2023**|2022|
||**£**|£|
|Depreciation - owned assets|**5,412**|5,412|
## **11. NET INCOME/(EXPENDITURE)**
## **12. TRUSTEES' REMUNERATION AND BENEFITS**
There were no trustees' remuneration or other benefits for the year ended 30 April 2023 nor for the year ended 30 April 2022.
## **Trustees' expenses**
There were no trustees' expenses paid for the year ended 30 April 2023 nor for the year ended 30 April 2022.
## **13. STAFF COSTS**
|Wages and salaries
Other pension costs
The average monthly number of employees during the year was as follows:
Administration|**2023**
**£**
**62,761**
**1,541**
**64,302**
**2023**
**3**|2022
£
56,269
2,906|
|---|---|---|
|||59,175|
|||2022
3|
No staff receive more than £60,000 per annum either this year or the prior year.
continued...
Page 18
**HEARTBURN CANCER UK**
**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
|**14.**
**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**
Unrestricted
fund
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
56,568
**Charitable activities**
Other charitable activities
-
Other trading activities
651
Investment income
12
**Total**
57,231
**EXPENDITURE ON**
Raising funds
25,548
**Charitable activities**
Early diagnosis
-
Awareness
9,907
Research and education
4,204
Support
9,026
Charity running costs
10,515
Other charitable activities
-
**Total**
59,200
**NET INCOME/(EXPENDITURE)**
(1,969)
**RECONCILIATION OF FUNDS**
Total funds brought forward
86,190
**TOTAL FUNDS CARRIED FORWARD**
84,221|Restricted
funds
£
73,524
37,143
-
-
110,667
22,987
24,934
22,846
3,125
-
3,000
-
76,892
33,775
40,248
74,023|Total
funds
£
130,092
37,143
651
12|
|---|---|---|
|||167,898|
|||48,535
24,934
32,753
7,329
9,026
13,515
-|
|||136,092|
|||31,806
126,438|
|||158,244|
continued...
Page 19
**HEARTBURN CANCER UK**
**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
## **15. TANGIBLE FIXED ASSETS**
|**COST**
At 1 May 2022 and 30 April 2023
**DEPRECIATION**
At 1 May 2022
Charge for year
At 30 April 2023
**NET BOOK VALUE**
At 30 April 2023
At 30 April 2022
**16.**
**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Prepayments and accrued income
**17.**
**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Accruals and deferred income|Plant and
machinery
£
**27,058**
**5,412**
**5,412**
**10,824**
**16,234**
21,646
**2023**
2022
**£**
£
**12,168**
36,666
**2023**
2022
**£**
£
**2,500**
17,845|
|---|---|
continued...
Page 20
**HEARTBURN CANCER UK**
**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
## **18. MOVEMENT IN FUNDS**
|**Unrestricted funds**
General fund
**Restricted funds**
Cytosponge Mobile Diagnostic Unit -
operation
Cytosponge Mobile Diagnostic Unit -
Essex & Suffolk
Cytosponge Mobile Diagnostic Unit -
purchase
Return to fitness
Awareness - North West of England
Awareness - London
HCUK East Anglia
Core costs
Support project
Early diagnosis
**TOTAL FUNDS**
Net movement in funds, included in the above are as follows:
**Unrestricted funds**
General fund
**Restricted funds**
Cytosponge Mobile Diagnostic Unit -
operation
Cytosponge Mobile Diagnostic Unit -
Essex & Suffolk
Core costs
Support project
Early diagnosis
**TOTAL FUNDS**|At 1.5.22
£
**84,221**
**41,114**
**10,000**
**17,156**
**1,000**
**2,102**
**500**
**2,151**
**-**
**-**
**-**
**74,023**
**158,244**
Incoming
resources
£
**91,588**
**53,190**
**-**
**8,000**
**12,000**
**10,135**
**83,325**
**174,913**|Net
movement
At
in funds
30.4.23
£
£
**3,860**
**88,081**
**35,098**
**76,212**
**(10,000)**
**-**
**-**
**17,156**
**-**
**1,000**
**-**
**2,102**
**-**
**500**
**-**
**2,151**
**8,000**
**8,000**
**12,000**
**12,000**
**10,135**
**10,135**
**55,233**
**129,256**
**59,093**
**217,337**
Resources
Movement
expended
in funds
£
£
**(87,728)**
**3,860**
**(18,092)**
**35,098**
**(10,000)**
**(10,000)**
**-**
**8,000**
**-**
**12,000**
**-**
**10,135**
**(28,092)**
**55,233**
**(115,820)**
**59,093**|
|---|---|---|
continued...
Page 21
**HEARTBURN CANCER UK**
**NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
## **18. MOVEMENT IN FUNDS - continued**
## **Comparatives for movement in funds**
|At 1.5.21
£
**Unrestricted funds**
General fund
86,190
**Restricted funds**
HCUK Augis RCS
3,125
Cytosponge Mobile Diagnostic Unit -
operation
31,370
Cytosponge Mobile Diagnostic Unit -
Essex & Suffolk
-
Cytosponge Mobile Diagnostic Unit -
purchase
-
Return to fitness
1,000
Awareness - North West of England
2,102
Awareness - London
500
HCUK East Anglia
2,151
40,248
**TOTAL FUNDS**
126,438
Comparative net movement in funds, included in the above are as follows:
Incoming
resources
£
**Unrestricted funds**
General fund
57,231
**Restricted funds**
HCUK Augis RCS
-
Cytosponge Mobile Diagnostic Unit -
operation
34,677
Cytosponge Mobile Diagnostic Unit -
Essex & Suffolk
10,000
Cytosponge Mobile Diagnostic Unit -
purchase
40,143
Staff costs
3,000
Awareness
22,847
110,667
**TOTAL FUNDS**
167,898|Net
movement
At
in funds
30.4.22
£
£
(1,969)
84,221
(3,125)
-
9,744
41,114
10,000
10,000
17,156
17,156
-
1,000
-
2,102
-
500
-
2,151
33,775
74,023
31,806
158,244
Resources
Movement
expended
in funds
£
£
(59,200)
(1,969)
(3,125)
(3,125)
(24,933)
9,744
-
10,000
(22,987)
17,156
(3,000)
-
(22,847)
-
(76,892)
33,775
(136,092)
31,806|
|---|---|
continued...
Page 22
**HEARTBURN CANCER UK NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
## **18. MOVEMENT IN FUNDS - continued**
## **Cytosponge Mobile Diagnostic Unit - operation**
To fund the purchase of a Mobile Diagnostic Unit and related equipment, which are accounted for as fixed assets and will be depreciated from May 2021, and fund the running costs of the unit. The unit is currently being deployed to support the DELTA project to demonstrate the efficacy of the "Cytosponge" in promoting early diagnosis of Oesophageal Cancer and/or Barrett's Oesophagus.
## **Cytosponge Mobile Diagnostic Unit - Essex and Suffolk**
To operate the mobile diagnostic unit in delivering the "Cytosponge" in promoting early diagnosis of Oesophageal Cancer and/or Barrett's Oesophagus in the Essex and Suffolk regions.
## **Cytosponge Mobile Diagnostic Unit - purchase**
Funds raising from the Golf Day event arranged to fund the purchase of an additional Mobile Diagnostic Unit and related equipment.
## **Return to fitness**
To support a research project into a programme to support Oesophageal Cancer patients recovering after treatment.
## **Awareness - North West of England**
Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus, in the North West of England.
## **Awareness- London**
Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus, in the London area.
## **HCUK East Anglia**
To fund the activities of the East Anglia support group with funds generated by the support group itself.
## **Awareness**
Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus.
## **Core costs**
Funds to support the core costs of the charity.
## **Support projects**
Funds to support ongoing projects.
## **Early diagnosis**
Funds to support early diagnosis of Oesophageal Cancer and/or Barrett's Oesophagus
continued...
Page 23
**HEARTBURN CANCER UK NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2023**
## **19. RELATED PARTY DISCLOSURES**
Duringthe year Absolutely Offices Limited, of which Beryl Huntingdon,a trustee of the charitable company, is a director, provided office services to the charity on normal commercial terms totalling £1,032 (2022: £705).
In addition Absolutely Offices Limited provided the office space free of charge as a donation in kind and has been accounted for within donations totalling £9,000 (2022: £10,044).
Page 24